Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,024 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells.
Park SH, Kim JH, Ko E, Kim JY, Park MJ, Kim MJ, Seo H, Li S, Lee JY. Park SH, et al. Among authors: seo h. FASEB J. 2018 May 29:fj201800011R. doi: 10.1096/fj.201800011R. Online ahead of print. FASEB J. 2018. PMID: 29812969
Our data suggest that disruption of the Keap1-Nrf2 pathway is one of the mechanisms by which EGFR-TKI resistance occurs, a fact that must be considered when treating patients with EGFR-TKI.-Park, S.-H., Kim, J. H., Ko, E., Kim, J.-Y., Park, M.-J., Kim, M. J., Seo …
Our data suggest that disruption of the Keap1-Nrf2 pathway is one of the mechanisms by which EGFR-TKI resistance occurs, a fact that must be …
Negative regulation of NOD1 mediated angiogenesis by PPARγ-regulated miR-125a.
Kang H, Park Y, Lee A, Seo H, Kim MJ, Choi J, Jo HN, Jeong HN, Cho JG, Chang W, Lee MS, Jeon R, Kim J. Kang H, et al. Among authors: seo h. Biochem Biophys Res Commun. 2017 Jan 1;482(1):28-34. doi: 10.1016/j.bbrc.2016.11.032. Epub 2016 Nov 9. Biochem Biophys Res Commun. 2017. PMID: 27836539
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
Necchi A, Roumiguié M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Necchi A, et al. Among authors: seo hk. Lancet Oncol. 2024 May 10:S1470-2045(24)00178-5. doi: 10.1016/S1470-2045(24)00178-5. Online ahead of print. Lancet Oncol. 2024. PMID: 38740030
5,024 results